Eugenia Accorsi Buttini

Objectives In retroperitoneal fibrosis (RPF), glucocorticoids (GC), alone or in combination with immunosuppressive agents, induce remission in 80%–90% of patients but up to two thirds of them relapse. There is limited knowledge on outcome predictors in RPF. We aimed to identify clinical, laboratory and imaging predictors of remission and relapse in RPF. Methods We included consecutive RPF patients treated with 6–9-month courses of GC with/without immunosuppressive agents.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

[18F]-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has become valuable in diagnosing and monitoring idiopathic retroperitoneal fibrosis (RPF). In a cohort of 49 patients with idiopathic RPF, Fernando and colleagues [1][1] investigated whether 18F-FDG-PET predicts response to glucocorticoid therapy.